Prominent France based interventional radiologist to leverage his expertise to assist the Company to achieve its future objective for the LIBERTY® Robotic System HINGHAM, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), which continues to build a network of global leaders in the endovascular interventional space […]
Other News
Tenax Therapeutics Announces the Evaluation of Strategic Alternatives
MORRISVILLE, N.C., Sept. 15, 2022 (GLOBE NEWSWIRE) — Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that the Company is evaluating alternative strategic paths focused on maximizing shareholder value. […]
TRiCares Raises €47m in a First Closing of its Series C Financing to Fund Further Development of Minimally Invasive Treatment for Tricuspid Regurgitation
TRiCares Raises €47m in a First Closing of its Series C Financing to Fund Further Development of Minimally Invasive Treatment for Tricuspid Regurgitation Paris, France and Munich, Germany, September 15, 2022 – TRiCares SAS (“TRiCares”) a privately held pioneer in the field of minimally invasive treatment of tricuspid regurgitation, is pleased to announce today that it has successfully raised €47m from the […]
Cardiology Compensation and New Patient Visits Rebound, Survey Finds
10th annual MedAxiom cardiovascular provider compensation and production report reveals year-over-year comparisons and decade trends NEPTUNE BEACH, Fla.–(BUSINESS WIRE)–MedAxiom, the premier source for cardiovascular organizational performance solutions, has released its 10th annual that includes data from the largest number of providers since its debut. The report features a special section on 10-year […]
Valbiotis Provides an Update on Its Progress and Publishes Its Financial Report for the First Half of 2022
A cash position of €15.4 million at June 30, 2022. Financial visibility until the last quarter of 2023, excluding potential additional revenues. Continued execution of the strategic and operational roadmap for future commercialization. LA ROCHELLE, France–(BUSINESS WIRE)–Regulatory News: Valbiotis (FR0013254851 – ALVAL / PEA/SME eligible) (Paris:ALVAL), a Research and Development […]
JenaValve Completes Enrollment in the ALIGN-AR IDE Clinical Trial
Landmark ALIGN-AR Pivotal IDE Study Intended to Evaluate Use of the Trilogy™ Heart Valve System in Treatment of High Surgical Risk Patients with Symptomatic, Severe Aortic Regurgitation IRVINE, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) — JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today […]
Caladrius Biosciences Announces Approval of Merger and Name Change to Lisata Therapeutics
All Merger-related proposals approved at the Annual Meeting of Stockholders BASKING RIDGE, N.J., Sept. 14, 2022 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), announced today that, based upon the final vote count certified by the independent inspector of elections for the annual meeting of stockholders […]
Cardiac Implants Announces Successful Therapeutic Adjustment Procedure Using Tri-Ring™ Percutaneous Annuloplasty Device
First-of-its-kind Annuloplasty device deployed and subsequent adjustment of the ring system demonstrates the advantage of a two-stage approach using a device specifically designed for the tricuspid heart valve AMERICAN CANYON, Calif.–(BUSINESS WIRE)–Cardiac Implants LLC has announced the successful initial deployment of its Annuloplasty ring with implementation of a therapeutic adjustment procedure […]
DiaMedica Therapeutics Appoints Julie Daves as SVP, Clinical Development Operations
Leadership Team Continues to Expand with Addition of Key Leader in Clinical Operations “Julie brings nearly two decades of clinical development operations experience to DiaMedica across a wide breadth of pharmaceutical therapeutic areas, including Phase 3 pivotal programs. She is an expert in trial execution and management of the myriad […]
Secant Group, Nationwide Children’s Hospital Collaborate to Advance Breakthrough Cardiovascular Technology
Novel polymer technology helps researchers edge closer to a solution for repairing congenital heart defects TELFORD, Pa.–(BUSINESS WIRE)–Secant Group, a leading implantable biomaterials developer based in suburban Philadelphia, PA, and a subsidiary of Solesis, has signed an agreement with The Abigail Wexner Research Institute at Nationwide Children’s Hospital in Columbus, OH, to explore potential […]



